ISRCTN25858715 https://doi.org/10.1186/ISRCTN25858715

The effects of Nocturnal Haemodialysis (NHD) compared to conventional haemodialysis on progression of Left Ventricular (LV) mass: a randomised controlled pilot study

Submission date
08/09/2004

Registration date
19/10/2004

Last Edited
20/09/2007

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Urological and Genital Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Bruce Culleton

Contact details
Foothills Hospital
1403-29th ST NW
Calgary
Canada
T2N 2T9
+1 403 944 8166
bruce.culleton@calgaryhealthregion.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives
Nocturnal haemodialysis and conventional three times per week haemodialysis will not differ with respect to progression of LV mass (measured using Cardiac Magnetic Resonance [CMR]) at 6 months.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
End-stage kidney disease

Interventions
Subjects are randomised to nocturnal haemodialysis or conventional three times per week haemodialysis (controls).

Intervention Type
Other

Phase
Not Specified

Primary outcome measure

Change in left ventricular mass (measured by CMR) at 6 months.

Secondary outcome measures
1. Mean change in systolic Blood Pressure (BP)
2. Change in HRQOL (Health-Related Quality-Of-Life)
3. Mean change in Haematocrit (Hct)/Erythropoietin (Epo) ratio
4. Mean change in calcium - phosphorus product

Overall study start date
01/08/2004

Completion date
30/06/2006

Eligibility

Key inclusion criteria
All adult haemodialysis patients in Alberta, Canada are eligible.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
38 subjects

Key exclusion criteria
Patients who are unable to perform NHD due to physical or mental incapacity.

Date of first enrolment
01/08/2004

Date of final enrolment
30/06/2006

Locations

Countries of recruitment
Canada

Study participating centre
Foothills Hospital
Calgary

Canada
T2N 2T9

Sponsor information

Organisation
Kidney Foundation of Canada (Canada)

Sponsor details
300-5165 Sherbrooke ST W
Montreal, Quebec
Canada
H4A 1T6
research@kidney.ca

Sponsor type
Research organisation

Website
http://www.kidney.ca/

ROR
https://ror.org/019a0gk53

Funder(s)

Funder type
Research organisation

Funder Name
Kidney Foundation of Canada (Canada)

Alternative Name(s)
La Fondation canadienne du rein, KFOC

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location
Canada

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	19/09/2007		Yes	No